INTRODUCTION
Malaria is the world's most important parasitic infection 1 . At present about 100 countries or territories in the world are considered malarious, almost half of which are in Africa, south of the Sahara 2 . The incidence of malaria worldwide is estimated to the 300-500 million clinical cases each year-majority caused by Plasmodium falciparum. Malaria is thought to kill between 1.1 & 2.7 million people worldwide each year 2 and kills a child somewhere in the world every 30 seconds 3 .
The treatment of Plasmodium falciparum malaria has been changed over the past two decades in response to declining sensitivity of Plasmodium falciparum to conventional antimalarial drugs 1 . The parasite remains fully sensitive to chloroquine only in Central America, north of the Panama Canal, in Haiti, Egypt and in scattered pockets of Asia and South America 4 . Southeast Asia, including India, lie in the zone of chloroquine resistance 2, 4 . However, world maps that depict countries as having or not having drug resistant malaria are potentially misleading, as there is great heterogeneity within countries and across boundaries. Local knowledge is therefore of paramount importance 4 .
The treatment of malaria depends on patient's age, the severity of infection, the likely pattern of susceptibility to antimalarial drugs, cost and availability of such drugs. For this reason recommendations vary according to geographic region and should be under constant review 1 . Though chloroquine is still the mainstay of antimalarial treatment, the emergence of Plasmodium falciparum resistant to this drug has challenged control efforts and has been linked to increased mortality 5 . Krishna 6 , stated that "assume that Plasmodium falciparum is chloroquine resistant unless in an area with known chloroquine sensitivity". White and Breman 7 , have opined "in areas where Plasmodium falciparum is still sensitive, chloroquine is used as the second drug". Todd et al. 8 , also agreed with this view and recommended that "Plasmodium falciparum is now resistant to chloroquine almost worldwide, notable in Asia and Africa, so quinine is the drug of choice as dihydrochloride or sulfate".
Quinine is a good alternative to chloroquine but it has several limitations 9 . It is used in combination with tetracyclines, such as doxycycline, in areas where quine resistance is also documented or possible. The artemisinin derivatives are better tolerated alternatives to quinine. Artemisinin and its derivatives are sesquiterpene lactone peroxides derived from the leaves the sweet wormwood (Artemisia annua) and related plants 4 . It has been used . Three derivatives are currently available-Artesunate, a water soluble form, and the lipid soluble Artemether and Arteether
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. Artemisinin derivatives kill all stages of malaria parasites, including 'young rings' by interacting with heme to produce carboncentered free radicals that alkylate proteins and membranes 11 . They have potent antimalarial activity, attractive safety profiles and are yet to be associated with significant resistance 5 . Qinghaosu and its derivatives have been studied extensively in China and Southeast Asia during the last 10 years. The effectiveness of these drugs in clearing parasites has been thoroughly documented 12 .
The essence of our study is to search for a better combination regimen in comparison to the older quininedoxycycline duo. There is growing belief among malariologists that to prevent resistance, falciparum malaria should no longer be treated with single drugs in endemic areas, the same strategy that has been applied to the treatment of other infectious diseases of major global public health significance such as tuberculosis and HIV/AIDS. This strategy is based upon simultaneous use of two or more drugs with different modes of action 7 . The basic tenet is that the probability of resistance developing simultaneously to two chemotherapeutic agents with independent mechanism of action is extremely low, of the order of once in 10 12 treatments. This frequency is the product of the probabilities of the acquisition of a resistant mutation to each drug multiplied by the number of parasites in a typical infection 3 . Combinations also prevent recrudescence or relapse of symptoms.
Combination of quinine with doxycycline is time-tested and retains at least 85% effectiveness nearly everywhere 1 . As quinine has limitations and artemisinin compounds are good alternatives, several drug combinations with artemisinin have been and are being evaluated till date. For example, artesunate plus amodiaquine, artemisinin derivative with mefloquine, artemether with lumefantrine and so on. Assessment of these and other effective and well-tolerated combination regimens containing artemisinin compounds is needed in other geographical areas 5 . In this scenario we conducted our study in this geographical area, Burdwan Medical College& Hospital, West Bengal, India. For our study we had chosen artemether in combination with doxycycline and compared to the standard quinine plus doxycycline regimens. All drugs were administered by the oral route.
MATERIALS AND METHODS
Study duration: For the individual patients, the study duration was 28 days including follow-up study visits. The entire study was completed from May 2007 to December 2010.
Ethical consideration:
This study was conducted in accordance with the principles enunciated in the Declaration of Helsinki for Biomedical Research involving Human Subjects. Also every effort was made to adhere to the spirit of the Good Clinical Practice guidelines of the Government of India 13 . Written informed consent was taken from each of the individuals. The protocol and the patients' informed consent form was approved by the Institutional Ethics Committee. 
Exclusion criteria: a)
Female subject who is pregnant or breast feeding.
b)
Estimated extent of parasitaemia > 10 5 /μL.
c)
Screening of peripheral blood smears showing presence of mixed malarial infection i.e. Plasmodium vivax + Plasmodium falciparum.
d)
Subject having evidence of  Impaired consciousness.  Severe anemia (Hb < 5 g/ dL).  Jaundice or compromised liver function (ALT or AST > 3 times upper limit of normal.
Subject having history of  Optic neuritis.
History of use of any antimalarial for the current febrile episode or within the past 1 month.
g)
History of use of any medication that may influence the activity of antimalarial drugs, e.g. folate, azithromycin, dapsone, etc. , within the past 7 days or longer depending upon the nature of the drug.
h)
History of Blood transfusion within the past 1 month.
i)
History of allergy (hypersensitivity) to artemether, quinine, doxycycline or closely related drugs.
j)
Any concomitant serious disorder of the kidney, heart, lungs or other vital organs.
k)
Unwilling to remain hospitalized for at least 7 days or to return for follow up at the stipulated days on 14 th day and 28 th days.
l)
History of alcohol or substance abuse.
Study Methodology:
a) Study design: Our study was post registration (Phase IV), prospective, open, randomized, controlled study with the two parallel treatment groups. b) Study time schedule: All the recruited subjects were admitted to the medicine inpatients departments and was studied as in-patient for 7 days. Thereafter they were discharged & was advised to come on the day 14 and 28 th days for follow up study. Detection of Plasmodium falciparum HRP-2 antigen by rapid dipstick antigen capture assay: Antibody capture of circulating plasmodium specific antigens -a technique proposed for rapid diagnosis of malaria 14 . The Plasmodium falciparum histidine rich protein-2 (PfHRP-2)-a water soluble antigen released by blood stages of the parasite-a target for antigen capture assay. Fifty μL blood placed in a labeled polypropylene tube and three drops (about 100 μL) of a RBC lysing agent added. After gently agitating the tubes, specimens were ready for testing by the antigen capture assay. Assay test sticks were made of cellulose fiber and contain an immobilized IgG 1 monoclonal antibody directed against the synthetic peptide (AHH [AHHAAD] 2 ) from PfHRP2. Test sticks were packaged with desiccant in foil pouches and kept unrefrigerated. One drop of a lysed blood specimen dispensed into one well of a ten-specimen test-stick holder platform. The end of a test-stick was placed in the drop of lysed blood. The drop of blood was absorbed by the teststick along its entire length, a process required 2-10 minutes depending on the specimen.PfHRP2 antigen detector reagent (containing polyclonal antibodies against PfHRP2 that conjugated to liposomes containing pink dye) was then added to every specimen well. After the antigen detector reagent was absorbed by the test-stick, a wash reagent was added and absorbed. The result was read immediately. A positive test result (PfHRP2) showed as a thin, solid, pink band that appeared on the dipstick. Different field studies showed that when Plasmodium falciparum asexual parasitemia is greater than 60 parasites per μL, the dipstick test is 96.5-100% sensitive 2 . At lower level of parasitemia the sensitivity decreases; however at 11-60 parasites per μL of blood, the assay still detects 70-80% of infection and at 10 parasites per μL of blood or less, the assay detects 11-67% of infection 13 . Since most individuals with symptomatic Plasmodium falciparum infection have greater than 60 parasites per μL of blood, the dipstick assay will be of particular use in rapid diagnosis of febrile patients and in epidemiologic field studies 12 .
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Furthermore because inexperienced microscopists often have difficulty in detecting less than 60 parasites per μL of blood, assessment of comparative sensitivity of blood films and dipstick assay among such technicians may indicate that dipstick has greater sensitivity than blood smear. Further the test is easy to perform, does not require electricity or elaborate equipment. Only a small amount of unprocessed whole blood is required. Analysis of a single specimen can be completed within 20 minutes. Usually PfHRP2 antigen is not detectable in blood 6 days after initiation of current chemotherapy suggesting that circulating antigen rarely lead to false positive test 14 . However, one problem with PfHRP-2 based tests is the persistence of HRP-2 antigen after effective treatment, possibly making these tests less suitable for identifying treatment failure 2 . Hence this test was not used during follow up period in this study. the patients who responded to treatment (fever clearance and parasite clearance were achieved) but showed recurrence of symptoms (i.e. fever) and or parasitemia before the end-of-trial visit on day 28 following commencement of study medication. 
RESULTS AND ANALYSIS
During the May 2007 to December 2010, total 84 patients were enrolled in this study. Out of that 43 patients were allocated randomly to the 1 st group, i.e. quinine plus doxycycline group. In that group 90.697% & 9.303% of patients were male and female respectively. Age range of that group was 15 to 60 years. All the patients were suffering from fever. Duration of fever before admission was 4.3 ± 2.89 (Mean ± SD) days and highest fever before treatment was 38.7 ± 0.69 (Mean ± SD) 0 C. In the 2 nd group 41 patients were allocated randomly i.e. they were belonged to artemether plus doxycycline group. In the 2 nd group 87.804% & 12.195% of patients were male and female respectively. Average age was 23.6 ± 7.01 (Mean ± SD) years. All were suffering from fever. Average duration of fever was 4.5 ± 3.59 (Mean ± SD) and highest temperature before treatment was 38.8 ± 0.68 (Mean ± SD) 0 C. The details of the Clinical and Laboratory characteristic of the both two groups of patients, before treatment started, are shown in the The nature and the severity of the adverse drug reactions were not significantly different in both the two groups. Headache, dizziness had been noticed in only 13 & 8 patients of the 2 nd group, while diarrhea was most common among the 44.186% of the patients of the 1 st group. 7 artemether + doxycycline, treated patients reported nausea and 10 patients reported vomiting after 48 hours of treatment, but no additional treatment was required. No patients were discontinued from the study drug treatment due to adverse drug reaction.
Serial blood examination showed that packed cell volume gradually increased after treatment in both the groups. Absolute neutrophil counts were low before treatment in 
DISCUSSION
Malaria is a protozoan disease transmitted by the bite of infected Anopheles mosquitoes. The most important of the parasitic diseases of humans, it is transmitted in 108 countries containing 3 billion people and causes nearly 1 million deaths each year 15 . Malaria has been eliminated from the United States, Canada, Europe, and Russia; in the late twentieth and early twenty-first centuries, however, its prevalence rose in many parts of the tropics 16 . Malaria can behave like an epidemic disease in some areas, particularly those with unstable malaria, such as northern India (the state of Rajasthan), Sri Lanka, Iraq, and Turkey, the horn of Africa, Rwanda, Burundi, southern Africa, Madagascar, and central Asia 17 .
Malaria is a very common cause of fever in tropical countries. William Osler 7 stated that "Humanity has but three great enemies. Fever, famine and war, of these by far the greatest, by far the terrible, is fever". The treatment of falciparum malaria has changed radically in recent years. In all endemic areas, the World Health Organization (WHO) 18 now recommends artemisinin-based combinations as first-line treatment for uncomplicated falciparum malaria. These rapidly and reliably effective drugs are sometimes unavailable in temperate countries, where treatment recommendations are limited by the registered available drugs. Fake or substandard antimalarials are commonly sold in many Asian and African countries. Thus, careful attention is required at the time of purchase and later, especially when the patient fails to respond as expected 18 . Current Artemisinin based combination regimens that are well tolerated in adults and children >5 kg include artemether-lumefantrine, artesunate-mefloquine, artesunate-amodiaquine, artesunate-sulfoxadine-pyrimethamine, and dihydroartemisinin-piperaquine & pyronaridine 19 .
But when we started our study, in the early 2007, we designed to use artemether plus doxycycline combination, by following the as usual strategy of the treatment of global public health importance, likes treatment of tuberculosis, HIV/AIDS, etc.
White NJ 20 stated that as a class, the artemisinins are very potent and fast-acting antimalarials, inducing more rapid parasite clearance and fever resolution than any other currently licensed antimalarial drug. They are particularly well suited for the treatment of P. falciparum malaria. . Artemisinins cause a significant reduction of the parasite burden, with a four-log 10 reduction in the parasite population for each 48-hour cycle of intra erythrocytic invasion, replication, and regress. As such, only three to four cycles (6-8 days) of treatment are required to remove all the parasites from the blood. Additionally, artemisinins possess some gametocytocidal activity, leading to a decrease in malarial parasite transmission. Artemisinins act early in the asexual parasite development cycle, whereas 
